维普期刊资源整合服务平台（V6.5）

113篇 您的检索式：作者名="Kostakoglu"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	疗效评价标准及其在淋巴瘤中的应用:第一部分显示文摘无论对于个体患者还是人群.癌症治疗的有效性都需要一种系统的、可重复的疗效评价方法。为满足这一需求,学界制定了一些评估疗效的指导原则,主要从解剖和代谢方面来量化治疗后的变化。过去几年针对特定的肿瘤组织制定了相应的疾病疗效分类标准迄今为止,恶性淋巴瘤可能是疾病疗效分类应用最普遍的肿瘤类型.该文对现有的淋巴瘤疗效评价标准进行概述,重点介绍这些评价标准各自的方法及其适用性。针对阻碍疗效评价标准化发展的问题,该文也对其中许多标准的技术复杂度和主观阈值判定的内容进行了评述。	Mateen C.Moghbel Laie Kostakoglu Katherine Zukotynski Delphine L.Chen Helen Nadel Ryan Niederkohr Erik Mittra 李慧玲(译) 兰晓莉刘振(审校)	2019	中华核医学与分子影像杂志2019，39，3：	3
2	PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease 显示文摘	Kostakoglu L Coleman M Leonard P	2002	J Nucl Med2002，43，8：	2
3	PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus显示文摘	Kostakoglu L Goldsmith S J	2004	J Nucl Med2004，45，1：	1
4	A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon tomography in the detection of nasopharyngeal carcinoma显示文摘	Kostakoglu L Uysal U Ozyar E	1997	Eur J Nucl Med1997，24，6：	1
5	Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors显示文摘	Elahi N Kiratli P	1997	J Nucl Med1997，38，7：	1
6	18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma显示文摘	Kostakoglu L Goldsmith SJ	2003	JNucl Med2003，44，2：	1
7	Role of imaging inthe staging and response assessment of lymphoma : consensus of theinternational conference on malignant lymphomas imaging workinggroup显示文摘	Barrington SF Mikhaeel NG Kostakoglu L	2014	J Clin Oncol2014，32，27：	1
8	PET predicts prognosis afterl cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease显示文摘	Kostakoglu L Coleman M Leonard JP	2002	J Nucl Med2002，43，8：	1
9	Monitoring response to therapy with thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma 显示文摘	Kostakoglu L Uysal U Ozyar E	1997	J Nucl Med1997，38，7：	1
10	Pre-and post-therapy thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma显示文摘	Kostakoglu L Uysal U Ozyar E	1996	J Nucl Med1996，37，12：	1
11	State-of-the-art research on ' lymphomas:role of molecular imaging for staging, prognostic evaluation, and treat-ment response' 显示文摘	Kostakoglu L Cheson BD	2013	Front Oncol2013，3，：	1
12	Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen显示文摘	NEIL H. BANDER EDOUARD J. TRABULSI LALE KOSTAKOGLU DANIEL YAO SHANKAR VALLABHAJOSULA PETER SMITH-JONES MAUREEN A. JOYCE MATTHEW MILOWSKY DAVID M. NANUS STANLEY J. GOLDSMITH	2003	The Journal of Urology2003，，5：	1
13	PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus显示文摘	Kostakoglu L Goldsmith SJ	2004	J Nucl Med2004，45，1：	1
14	Speech-relat ed visualization of laryngeal muscles with fluorine-18-FDG 显示文摘	Kostakoglu L Wong JC Barrington SF	1996	J NuclMed1996，37，：	1
15	Abbreviated chemotherapy with fludarabine followed by tositumomab and Iodine131 Tositumomab for untreated follicular lymphoma显示文摘	Leonard J Coleman M Kostakoglu L	2005	J Clin Oncol2005，23，24：	1
16	Impact of radiotherapy on normal brain tissue: semi-automated quantification of decrease in perfusion显示文摘	Gulaldi N Kostakoglu L Uzal D	2000	Ann Nucl Med2000，14，1：	1
17	Clinical use of monoclonal antibody huJ591 therapy: targeting prostate specific membrane antigen 显示文摘	Nanus DM Milowsky MI Kostakoglu L	2003	J Urology2003，170，6：	1
18	Clinical role of FDG PET in cvalution of cancer patients显示文摘	Kostakoglu L Agress H Goldsmith S J	2003	RadioGraphics2003，23，：	1
19	Clinical role of FDG PET in evaluation of cancer patients显示文摘	Kostakoglu L Agress Jr H Goldsmith S J	2003	Radiographics2003，23，：	1
20	Expansion of fascial flaps: histopathologic changes and clinical benefits 显示文摘	Kostakoglu N Kecik A Ozyilmaz FT	1993	Plast Reconstr Surg1993，91，：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示